Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study

W. C. Koller; G. A. Block; J. E. Ahlskog; S. Ahrens; J. M. Cedarbaum; G. Cyhan; C. G. Goetz; P. A. LeWitt; C. Liss; L. McLean; H. Moses; M. D. Muenter; P. Nausieda; J. Sanchez-Ramos; S. Reich; C. Singer; S. Stellar; W. J. Weiner

doi:10.1097/00002826-199108000-00004

Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study

W. C. Koller, G. A. Block, J. E. Ahlskog, S. Ahrens, J. M. Cedarbaum, G. Cyhan, C. G. Goetz, P. A. LeWitt, C. Liss, L. McLean, H. Moses, M. D. Muenter, P. Nausieda, J. Sanchez-Ramos, S. Reich, C. Singer, S. Stellar, W. J. Weiner

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.

Original language	English
Pages (from-to)	322-329
Number of pages	8
Journal	Clinical Neuropharmacology
Volume	14
Issue number	4
DOIs	https://doi.org/10.1097/00002826-199108000-00004
State	Published - 1991
Externally published	Yes

Keywords

MK-458
Parkinson's disease

Access to Document

10.1097/00002826-199108000-00004

Cite this

Koller, W. C., Block, G. A., Ahlskog, J. E., Ahrens, S., Cedarbaum, J. M., Cyhan, G., Goetz, C. G., LeWitt, P. A., Liss, C., McLean, L., Moses, H., Muenter, M. D., Nausieda, P., Sanchez-Ramos, J., Reich, S., Singer, C., Stellar, S., & Weiner, W. J. (1991). Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. Clinical Neuropharmacology, 14(4), 322-329. https://doi.org/10.1097/00002826-199108000-00004

@article{e0944825074147f2a0ccc98c18f04d06,

title = "Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study",

abstract = "Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.",

keywords = "MK-458, Parkinson's disease",

author = "Koller, {W. C.} and Block, {G. A.} and Ahlskog, {J. E.} and S. Ahrens and Cedarbaum, {J. M.} and G. Cyhan and Goetz, {C. G.} and LeWitt, {P. A.} and C. Liss and L. McLean and H. Moses and Muenter, {M. D.} and P. Nausieda and J. Sanchez-Ramos and S. Reich and C. Singer and S. Stellar and Weiner, {W. J.}",

year = "1991",

doi = "10.1097/00002826-199108000-00004",

language = "English",

volume = "14",

pages = "322--329",

journal = "Clinical Neuropharmacology",

issn = "0362-5664",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

Koller, WC, Block, GA, Ahlskog, JE, Ahrens, S, Cedarbaum, JM, Cyhan, G, Goetz, CG, LeWitt, PA, Liss, C, McLean, L, Moses, H, Muenter, MD, Nausieda, P, Sanchez-Ramos, J, Reich, S, Singer, C, Stellar, S & Weiner, WJ 1991, 'Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study', Clinical Neuropharmacology, vol. 14, no. 4, pp. 322-329. https://doi.org/10.1097/00002826-199108000-00004

TY - JOUR

T1 - Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study

AU - Koller, W. C.

AU - Block, G. A.

AU - Ahlskog, J. E.

AU - Ahrens, S.

AU - Cedarbaum, J. M.

AU - Cyhan, G.

AU - Goetz, C. G.

AU - LeWitt, P. A.

AU - Liss, C.

AU - McLean, L.

AU - Moses, H.

AU - Muenter, M. D.

AU - Nausieda, P.

AU - Sanchez-Ramos, J.

AU - Reich, S.

AU - Singer, C.

AU - Stellar, S.

AU - Weiner, W. J.

PY - 1991

Y1 - 1991

N2 - Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.

AB - Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.

KW - MK-458

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0025771274&partnerID=8YFLogxK

U2 - 10.1097/00002826-199108000-00004

DO - 10.1097/00002826-199108000-00004

M3 - Article

C2 - 1913699

AN - SCOPUS:0025771274

SN - 0362-5664

VL - 14

SP - 322

EP - 329

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

IS - 4

ER -

Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study

Abstract

Keywords

Access to Document

Fingerprint

Cite this